Emerging Therapies in Prostate Cancer

Video

For High-Definition, Click

Raoul D. Concepcion, MD, introduces the topic of emerging therapies in patients with castration-resistant prostate cancer. Currently, in the docetaxel failure state, cabazitaxel, abiraterone, and enzalutamide are approved.

Concepcion highlights several key agents in phase III clinical trials. Alpharadin or radium-223 is an alpha radiopharmaceutical that has a narrow depth of penetration but has a survival benefit alone as well as response for pain relief and reduction of skeletal-related events.

Concepcion also mentions Oteronel or TAK-700, an oral agent, and Aragon or 509, an androgen signaling inhibitor.

Related Videos
Kathryn Beckermann, MD, PhD
Angela Jia, MD, PhD, of University Hospitals
Robert Wang, MD, of Fox Chase Cancer Center
Rohan Garje, MD, chief, Genitourinary Medical Oncology, Baptist Health Miami Cancer Institute
Jaime R. Merchán, MD
Nikhil A. Gopal, MD
Kara N. Maxwell, MD, PhD
Ruben Olivares, MD
Mike Lattanzi, MD, medical oncologist, Texas Oncology